Abstract

Lonza and Sanofi have signed a supply agreement under which the Swiss chemical maker will operate a large-scale mammalian cell culture facility dedicated to Sanofi at its site in Visp, Switzerland. It is Lonza’s first customer-dedicated biologics plant at the sprawling site, which more typically manufactures small molecules for drug industry customers. The firm operates three similar sites in Singapore and Portsmouth, N.H., its main biologics operation. Under the contract, Lonza will construct and operate the facility. The two partners will share available capacity with excess maintained to support increases in Sanofi’s demand. Lonza will be free to market its share of capacity as well as unused Sanofi capacity where available. The partners will invest $285 million for the first phase of the project, which is expected to come on-line in 2020. Approximately 60% of Sanofi’s pipeline is comprised of biologics, including monoclonal antibodies, being developed in therapeutic areas such

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.